Key Insights

Highlights

Success Rate

86% trial completion

Published Results

14 trials with published results (16%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

8.0%

7 terminated out of 87 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

15%

13 trials in Phase 3/4

Results Transparency

33%

14 of 42 completed with results

Key Signals

14 with results86% success

Data Visualizations

Phase Distribution

59Total
Not Applicable (18)
Early P 1 (2)
P 1 (6)
P 2 (20)
P 3 (13)

Trial Status

Completed42
Recruiting17
Unknown9
Terminated7
Active Not Recruiting5
Not Yet Recruiting4

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (87)

Showing 20 of 20 trials
NCT07569445RecruitingPrimary

Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome

NCT07150013Phase 1RecruitingPrimary

Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome

NCT07503444Phase 3Not Yet RecruitingPrimary

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT06840496Phase 3RecruitingPrimary

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

NCT07480564Phase 3Not Yet RecruitingPrimary

Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome

NCT05898620Phase 3RecruitingPrimary

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

NCT07418905Not ApplicableActive Not RecruitingPrimary

Technology-supported Motor Rehabilitation for People With Rett Syndrome

NCT04900493RecruitingPrimary

The Rett Syndrome Global Registry

NCT06139172Not ApplicableRecruiting

Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)

NCT05606614Phase 3RecruitingPrimary

A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)

NCT06338267RecruitingPrimary

Validating Innovative Biosensors for Rett Autonomic Symptom Tracking

NCT07257978Phase 2Not Yet Recruiting

Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

NCT05932589RecruitingPrimary

Neurophysiologic Biomarkers in Rett Syndrome

NCT06152237Phase 1Active Not RecruitingPrimary

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

NCT07151950Active Not Recruiting

Obi Medical Robot: Evaluating Effectiveness Related to Usability

NCT05740761RecruitingPrimary

Gene Editing as a Therapeutic Approach for Rett Syndrome

NCT03836300Not ApplicableEnrolling By Invitation

Parent and Infant Inter(X)Action Intervention (PIXI)

NCT04041713Phase 2Not Yet RecruitingPrimary

A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome

NCT06856759Early Phase 1RecruitingPrimary

Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome

NCT06705816RecruitingPrimary

Cognitive Function in Rett Syndrome During Trofinetide Treatment

Scroll to load more

Research Network

Activity Timeline